cd38 inhibitor and 5-amino-1mq synergy nad+ The Pharmacology of CD38/NADase: An emerging target for cancer aging diseases CD38-Induced Metabolic Dysfunction Primes Multiple
CD38 Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+ Lowering Agents A Potent and Specific CD38 Inhibitor Ameliorates Age Related Metabolic Dysfunction by Reversing Tissue NAD+ Decline: Cell Metabolism Frontiers CD38 in Adenosinergic Pathways and Metabolic Re programming in Human Multiple Myeloma Cells: In tandem Insights From Basic Science to Therapy CD38 as a Regulator of Cellular NAD: A Novel Potential Pharmacological Target for Metabolic Conditions PMC
Pay in 4 interest-free payments of $7.39 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5



